Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: MEDI4736|DRUG: MEDI9447
Sponsor: Jules Bordet Institute
Collaborators: AstraZeneca